A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients

Br J Haematol. 2020 Dec;191(5):927-930. doi: 10.1111/bjh.17076. Epub 2020 Sep 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bortezomib / administration & dosage
  • Bortezomib / adverse effects
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Panobinostat / administration & dosage
  • Panobinostat / adverse effects
  • Retrospective Studies

Substances

  • Bortezomib
  • Dexamethasone
  • Panobinostat